MGX
Metagenomi Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.475
Kõrge
$1.475
Madal
$1.475
Maht
0.25M
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika
Seotud uudised
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $12
Chardan Capital analyst Geulah Livshits maintains Metagenomi with a Buy and lowers the price target from $13 to $12.
Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $16
Wells Fargo analyst Yanan Zhu maintains Metagenomi with a Overweight and lowers the price target from $20 to $16.
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate
Metagenomi to Present at Upcoming Scientific Meetings
EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
Seotud aktsiad
WTFCM
Wintrust Financial Corporation Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series D
SND
Smart Sand Inc.
JEWL
Adamas One Corp.
ROP
Roper Technologies Inc.
FORM
FormFactor Inc. FormFactor Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.